Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: What next?

Trends in Parasitology

Volumn 17, Issue 12, 2001, Pages 582-588

  Sibley, Carol Hopkins ^a   Hyde, John E ^b   Sims, Paul F G ^b   Plowe, Christopher V ^c   Kublin, James G ^d   Mberu, Edward K ^e   Cowman, Alan F ^f   Winstanley, Peter A ^g   Watkins, William M ^g   Nzila, Alexis M ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

^d UNIVERSITY OF MALAWI   (Malawi)

^e KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^f WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; FANSIDAR; FOLIC ACID ANTAGONIST;

AFRICA SOUTH OF THE SAHARA; BIOAVAILABILITY; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG HALF LIFE; MALARIA FALCIPARUM; MUTATION; NONHUMAN; PARASITOLOGY; PLASMODIUM FALCIPARUM; PUBLIC HEALTH; REVIEW; SOUTH AMERICA; SOUTHEAST ASIA; TREATMENT FAILURE;

AFRICA SOUTH OF THE SAHARA; ANIMALS; ANTIMALARIALS; CHLOROQUINE; DRUG COMBINATIONS; DRUG RESISTANCE; HUMANS; MALARIA, FALCIPARUM; MICROBIAL SENSITIVITY TESTS; MUTATION; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT OUTCOME;

PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0035702490     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4922(01)02085-2     Document Type: Review

References (68)

1. Chloroquine in Africa: Critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa
2. Antimalarial drug resistance: The pace quickens
3. Epidemiology of drug resistance in malaria
4. In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment
5. Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine/pyrimethamine in isolates from Tanzania
6. Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in Uganda: Correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes
7. The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya
8. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites
9. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum
10. Kenyan Plasmodium falciparum field isolates: Correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain
11. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene
12. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: Dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine
13. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum
14. The mechanism of resistance to sulfa drugs in Plasmodium falciparum
15. The mechanisms of drug action and resistance in malaria
16. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria
17. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum
18. The dihydrofolate reductase-thymidylate synthase gene in the drug resistance of malaria parasites
19. Drug-resistant malaria: Laboratory and field investigations
20. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins
21. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase
22. Lead discovery of inhibitors of the dihydrofolate reductase domain of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase
23. Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum
24. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast
25. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria
26. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization
27. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum
28. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance
29. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs
30. Chemotherapy for falciparum malaria: The armoury, the problems and the prospects
31. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria
32. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance
33. Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: Pharmacokinetics and therapeutic range
34. Chlorproguanil-dapsone: Effective treatment for uncomplicated falciparum malaria
35. Drug-resistant falciparum malaria in Tanzania: Chlorproguanil-dapsone is effective treatment for infections resistant to pyrimethamine-sulfadoxine
36. The efficacy of antifolate antimalarial combinations in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses
37. PS-15: A potent, orally active antimalarial from a new class of folic acid antagonists
38. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance
39. Correlation of mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase with patterns of in vivo resistance to pyrimethamine-sulfadoxine
40. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites
41. Drug resistance in Pneumocystis carinii: An emerging problem
42. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy
43. Drug resistance in malaria
44. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance
45. Resistance of East African varieties of Plasmodium falciparum to pyrimethamine
46. Mass treatment with pyrimethamine
47. Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: A model for deterring resistance
48. In vitro susceptibility of Plasmodium falciparum malaria to pyrimethamine, sulfadoxine, trimetoprhim and sulfamethoxazole, singly and in combination
49. Resistance in vivo of Plasmodium falciparum to co-trimoxazole in western Uganda
50. Plasmodium falciparum clinical malaria: Lessons from longitudinal studies in Senegal
51. Detection of very low level Plasmodium falciparum infections using the nested polymerase chain reaction and a reassessment of the epidemiology of unstable malaria in Sudan
52. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique
53. Plasmodium falciparum: Detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion
54. P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: Epidemiology and role in clinical resistance to antifolates
55. Molecular assays for surveillance of antifolate-resistant malaria
56. High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/pyrimethamine resistance
57. Why is it that antimalarial drug treatments do not always work?
58. Using evidence to change antimalarial drug policy in Kenya
59. Making malaria-treatment policy in the face of drug resistance
60. Impact of chloroquine resistance on malaria mortality
61. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: Selective pressure for resistance is a function of long elimination half-life
62. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali
63. Delaying antimalarial drug resistance with combination chemotherapy
64. Averting a malaria disaster
65. The chemotherapy of rodent malaria, XL. The action of artemisinin and related sesquiterpenes
66. A clinical trial of combination of artesunate and mefloquine in the treatment of acute uncomplicated falciparum malaria: A short and practical regimen
67. A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria